PerkinElmer announced that it will acquire EuroImmun, a diagnostics company based in Lübeck, Germany, for approximately $1.3 billion in cash. EuroImmun specializes in autoimmune testing, and also has a high profile in infectious diseases and allergy testing with sales in more than 130 countries. PerkinElmer hopes that the deal will enable it to expand into the autoimmune and allergy diagnostic markets and also plans to market EuroImmun’s reproductive health technology in the U.S. “With the acquisition of EuroImmun and its talented team of professionals, we are able to leverage our combined advanced detection, imaging, and assay development capabilities, along with our strong collective market positions and synergistic commercial activities, to deliver better and more complete solutions to our customers around the world,” said Robert Friel, chairman and CEO of PerkinElmer.